search
Back to results

Non-oxidative Metabolite Profiles After Increasing Doses of Ethanol

Primary Purpose

Alcohol Consumption, Healthy

Status
Completed
Phase
Phase 1
Locations
Spain
Study Type
Interventional
Intervention
10 g ethanol
20 g ethanol
40 g ethanol
60 g ethanol
80 g ethanol
Sponsored by
Parc de Salut Mar
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Alcohol Consumption focused on measuring Ethanol, Fatty acid ethyl esters, Ethyl glucoronide, Ethyl sulphate, Pharmacokinetics

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Understand and accept the study's procedures and sign an informed consent form
  • No evidence of somatic or psychiatric disorders as per past medical history and physical examination
  • EKG, blood and urine tests taken before entry into the study within the normal range. Minor and transient abnormalities may be acceptable if, according to the Principal Investigator's criterion and the state of the art, they are felt to have no clinical relevance, entail no danger to the participant, and don't interfere with the product's assessment. These abnormalities and their non-relevance must be specifically justified in writing)
  • Body mass index (BMI=weight/heigth2) between 19 and 29 kg/m2, weight between 50 and 100 kg (for the 60 and 80 g doses, subjects will be required to weigh a minimum of 67 kg)
  • For premenopausal females, a regular menstrual cycle of 26-32 days duration.
  • Social or recreational alcohol consumption of at least 1 unit per day (or its equivalent [7 units] over the whole week) and having experienced drunkenness several times

Exclusion Criteria:

  • Evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of the drug or symptoms suggestive of drug-induced gastrointestinal irritation
  • Previous psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs
  • Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks
  • Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial
  • Individuals intolerant or having experienced a severe adverse reaction to alcohol
  • Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session
  • Smokers of >10 cigarettes/day
  • Consumption of >20 g/day of alcohol (females) or of >40 g/day (males)
  • Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study
  • Hepatitis B, hepatitis C or human immunodeficiency virus-positive individuals
  • Pregnant or lactating women, or those using hormonal or unreliable contraceptive methods during the study period. Complete abstinence, intrauterine devices, double barrier methods or a vasectomized sexual partner will be considered acceptable
  • Women with amenorrhea or suffering severe premenstrual syndrome
  • Individuals of Asian ascent

Sites / Locations

  • Parc de Salut Mar (IMIM)

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

10 g ethanol

20 g ethanol

40 g ethanol

60 g ethanol

80 g ethanol

Arm Description

Subjects will be required to drink a dilution of 31 mL of vodka in 369 mL of lemon-flavored water in 15 minutes.

Subjects will be required to drink a dilution of 63 mL of vodka in 337 mL of lemon-flavored water in 15 minutes.

Subjects will be required to drink a dilution of 125 mL of vodka in 275 mL of lemon-flavored water in 15 minutes.

Subjects will be required to drink a dilution of 188 mL of vodka in 212 mL of lemon-flavored water in 15 minutes.

Subjects will be required to drink a dilution of 250 mL of vodka in 150 mL of lemon-flavored water in 15 minutes.

Outcomes

Primary Outcome Measures

Area Under the Concentration-Time Curve (AUC 0-24h)
Calculation of the AUC for plasma fatty acid ethyl esters (palmitic, stearic, linoleic and oleic acid ethyl esters) concentrations. Blood samples will be obtained baseline and at 0,25, 0,50, 0,75,1, 1,25, 1,50, 1,75, 2, 2,5, 3, 3,5, 4, 5, 6, 8, 10, 24h. Additional samples will be collect at 72 h and 1 week, 1 and 2 months after administration. At 3 months a sample will be obtained in selected participants.

Secondary Outcome Measures

Area Under the Concentration-Time Curve (AUC 0-24h)
Calculation of the AUC for plasma and saliva concentrations of ethanol and its non-oxidative metabolites ethyl sulphate and ethyl glucoronide. Blood samples will be obtained baseline and at 0,25, 0,50, 0,75,1, 1,25, 1,50, 1,75, 2, 2,5, 3, 3,5, 4, 5, 6, 8, 10, 24. Additional samples will be collected at 72 h and 1 week, 1 month and 2 months after administration. At 3 months a sample in selected participants. Saliva samples at baseline and 0,5, 1, 2, 3, 4, 6, 10 and 24 h after administration
Cumulative amount of drug excreted into urine up to collection time of last measurable concentration
Urine will be collected in the following intervals 0-6h, 6-12h, 12-24h, 24-48h, 48-72h and the total amount of ethanol and its non-oxidative metabolites ethyl sulphate and ethyl glucoronide will be calculated.
Elimination half-life
Calculation of elimination half-life from ethanol and its non-oxidative metabolites (fatty acid ethyl esters, ethyl sulphate and ethyl glucoronide) concentrations in plasma
Fatty acid ethyl esters and ethyl glucoronide hair concentrations
Concentrations of fatty acid ethyl esters and ethyl glucoronide in hair at baseline, one and two month after administration. An additional sample at 3 months in selected participants.
Change in subjective effects of ethanol
Participants will self-report their experience on a visual analogue scale of drunkenness and Biphasic alcohol effects scale (BAES) at baseline and 0.5,0.75,1,1.5,2,4,6,8,10 after administration.
Number of Participants with Serious and Non-Serious Adverse Events
Collection of adverse effects spontaneously reported by the participants and/or observed by the investigators
Change in Addiction Research Center Inventory (ARCI)
ARCI will be administered baseline and 10 h after administration (subjects should answer at 10 h remembering their experience at the moment of maximum effects)
Change in Evaluation of Subjective Effects of Substances with Abuse Potential (VESSPA)
VESSPA will be administered baseline and 10 h after administration (subjects should answer at 10 h remembering their experience at the moment of maximum effects)
Ethanol dose identification questionaire
Participants should guess the dose they have ingested during the experimental session among 5 options (10, 20, 40, 60 and 80 g of ethanol)
Urinary drug concentrations
Urinary concentrations of ethanol and its non-oxidative metabolites ethyl sulphate and ethyl glucoronide will measured at 1 week, 1 and 2 months after administration (3 months in selected subjects)

Full Information

First Posted
December 3, 2014
Last Updated
May 13, 2016
Sponsor
Parc de Salut Mar
search

1. Study Identification

Unique Protocol Identification Number
NCT02311686
Brief Title
Non-oxidative Metabolite Profiles After Increasing Doses of Ethanol
Official Title
Identifying the Profile of the Main Non-oxidative Biomarkers of Alcohol (Ethyl Glucuronide, Ethyl Sulphate, Fatty Acid Ethyl Esters) After the Experimental Exposure to Increasing Doses of Alcohol in Adults.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Completed
Study Start Date
December 2014 (undefined)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
May 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Parc de Salut Mar

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the study is to study the profile of ethanol and non-oxidative biomarkers (ethyl glucuronide, ethyl sulphate and fatty acid ethyl esters) after experimental administration of increasing doses of alcohol in adult subjects.
Detailed Description
The abuse of alcohol causes serious health and social problems. Alcohol consumption can be monitored by detecting biomarkers. In current practice indirect biomarkers (mean corpuscular volume, transaminases, gammaglutamyl or carbohydrate-deficient transferrin) are used, although direct biomarkers of alcohol, including alcohol itself and metabolites also exist. Biomarkers of alcohol consumption are used as tools to prevent health and social problems related with alcohol, allowing the identification of subjects at risk of abuse, dependence or withdrawal and to assess the efficacy of treatments for alcohol dependence. Non-oxidative metabolites (ethyl glucuronide, ethyl sulphate and fatty acid ethyl esters) have longer biological half-life than ethanol and accumulate in tissues after consumption. The objective of the study is to study the profile of ethanol and non-oxidative biomarkers (ethyl glucuronide, ethyl sulphate and fatty acid ethyl esters) after experimental administration of increasing doses of alcohol in adult subjects. Subjects will be genotyped for genetic polymorphisms of proteins related to ethanol metabolism and effects (as alcohol dehydrogenase and aldehyde dehydrogenase), and the genotypes will be used to evaluate their influence in the results.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Consumption, Healthy
Keywords
Ethanol, Fatty acid ethyl esters, Ethyl glucoronide, Ethyl sulphate, Pharmacokinetics

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
10 g ethanol
Arm Type
Experimental
Arm Description
Subjects will be required to drink a dilution of 31 mL of vodka in 369 mL of lemon-flavored water in 15 minutes.
Arm Title
20 g ethanol
Arm Type
Experimental
Arm Description
Subjects will be required to drink a dilution of 63 mL of vodka in 337 mL of lemon-flavored water in 15 minutes.
Arm Title
40 g ethanol
Arm Type
Experimental
Arm Description
Subjects will be required to drink a dilution of 125 mL of vodka in 275 mL of lemon-flavored water in 15 minutes.
Arm Title
60 g ethanol
Arm Type
Experimental
Arm Description
Subjects will be required to drink a dilution of 188 mL of vodka in 212 mL of lemon-flavored water in 15 minutes.
Arm Title
80 g ethanol
Arm Type
Experimental
Arm Description
Subjects will be required to drink a dilution of 250 mL of vodka in 150 mL of lemon-flavored water in 15 minutes.
Intervention Type
Dietary Supplement
Intervention Name(s)
10 g ethanol
Other Intervention Name(s)
Vodka Absolut®
Intervention Description
Alcohol single oral dose
Intervention Type
Dietary Supplement
Intervention Name(s)
20 g ethanol
Other Intervention Name(s)
Vodka Absolut®
Intervention Description
Alcohol single oral dose
Intervention Type
Dietary Supplement
Intervention Name(s)
40 g ethanol
Other Intervention Name(s)
Vodka Absolut®
Intervention Description
Alcohol single oral dose
Intervention Type
Dietary Supplement
Intervention Name(s)
60 g ethanol
Other Intervention Name(s)
Vodka Absolut®
Intervention Description
Alcohol single oral dose
Intervention Type
Dietary Supplement
Intervention Name(s)
80 g ethanol
Other Intervention Name(s)
Vodka Absolut®
Intervention Description
Alcohol single oral dose
Primary Outcome Measure Information:
Title
Area Under the Concentration-Time Curve (AUC 0-24h)
Description
Calculation of the AUC for plasma fatty acid ethyl esters (palmitic, stearic, linoleic and oleic acid ethyl esters) concentrations. Blood samples will be obtained baseline and at 0,25, 0,50, 0,75,1, 1,25, 1,50, 1,75, 2, 2,5, 3, 3,5, 4, 5, 6, 8, 10, 24h. Additional samples will be collect at 72 h and 1 week, 1 and 2 months after administration. At 3 months a sample will be obtained in selected participants.
Time Frame
From baseline to 24 hours after administration
Secondary Outcome Measure Information:
Title
Area Under the Concentration-Time Curve (AUC 0-24h)
Description
Calculation of the AUC for plasma and saliva concentrations of ethanol and its non-oxidative metabolites ethyl sulphate and ethyl glucoronide. Blood samples will be obtained baseline and at 0,25, 0,50, 0,75,1, 1,25, 1,50, 1,75, 2, 2,5, 3, 3,5, 4, 5, 6, 8, 10, 24. Additional samples will be collected at 72 h and 1 week, 1 month and 2 months after administration. At 3 months a sample in selected participants. Saliva samples at baseline and 0,5, 1, 2, 3, 4, 6, 10 and 24 h after administration
Time Frame
From baseline to 24 hours after administration
Title
Cumulative amount of drug excreted into urine up to collection time of last measurable concentration
Description
Urine will be collected in the following intervals 0-6h, 6-12h, 12-24h, 24-48h, 48-72h and the total amount of ethanol and its non-oxidative metabolites ethyl sulphate and ethyl glucoronide will be calculated.
Time Frame
From baseline to 72 hours after administration
Title
Elimination half-life
Description
Calculation of elimination half-life from ethanol and its non-oxidative metabolites (fatty acid ethyl esters, ethyl sulphate and ethyl glucoronide) concentrations in plasma
Time Frame
From baseline to 24 hours after administration
Title
Fatty acid ethyl esters and ethyl glucoronide hair concentrations
Description
Concentrations of fatty acid ethyl esters and ethyl glucoronide in hair at baseline, one and two month after administration. An additional sample at 3 months in selected participants.
Time Frame
Baseline, 1 and 2 months after administration
Title
Change in subjective effects of ethanol
Description
Participants will self-report their experience on a visual analogue scale of drunkenness and Biphasic alcohol effects scale (BAES) at baseline and 0.5,0.75,1,1.5,2,4,6,8,10 after administration.
Time Frame
From baseline to 10 hours after administration
Title
Number of Participants with Serious and Non-Serious Adverse Events
Description
Collection of adverse effects spontaneously reported by the participants and/or observed by the investigators
Time Frame
From baseline to 24 hours after administration
Title
Change in Addiction Research Center Inventory (ARCI)
Description
ARCI will be administered baseline and 10 h after administration (subjects should answer at 10 h remembering their experience at the moment of maximum effects)
Time Frame
From baseline to 10 h after administration
Title
Change in Evaluation of Subjective Effects of Substances with Abuse Potential (VESSPA)
Description
VESSPA will be administered baseline and 10 h after administration (subjects should answer at 10 h remembering their experience at the moment of maximum effects)
Time Frame
From baseline to 10 h after administration
Title
Ethanol dose identification questionaire
Description
Participants should guess the dose they have ingested during the experimental session among 5 options (10, 20, 40, 60 and 80 g of ethanol)
Time Frame
10 h after administration
Title
Urinary drug concentrations
Description
Urinary concentrations of ethanol and its non-oxidative metabolites ethyl sulphate and ethyl glucoronide will measured at 1 week, 1 and 2 months after administration (3 months in selected subjects)
Time Frame
From 1 week to 2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Understand and accept the study's procedures and sign an informed consent form No evidence of somatic or psychiatric disorders as per past medical history and physical examination EKG, blood and urine tests taken before entry into the study within the normal range. Minor and transient abnormalities may be acceptable if, according to the Principal Investigator's criterion and the state of the art, they are felt to have no clinical relevance, entail no danger to the participant, and don't interfere with the product's assessment. These abnormalities and their non-relevance must be specifically justified in writing) Body mass index (BMI=weight/heigth2) between 19 and 29 kg/m2, weight between 50 and 100 kg (for the 60 and 80 g doses, subjects will be required to weigh a minimum of 67 kg) For premenopausal females, a regular menstrual cycle of 26-32 days duration. Social or recreational alcohol consumption of at least 1 unit per day (or its equivalent [7 units] over the whole week) and having experienced drunkenness several times Exclusion Criteria: Evidence of a preexisting condition (including gastrointestinal, liver, or kidney disorders) that may alter the absorption, distribution, metabolism or excretion of the drug or symptoms suggestive of drug-induced gastrointestinal irritation Previous psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial Individuals intolerant or having experienced a severe adverse reaction to alcohol Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session Smokers of >10 cigarettes/day Consumption of >20 g/day of alcohol (females) or of >40 g/day (males) Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or xanthine-containing beverages in the 3 months prior to inclusion in the study Hepatitis B, hepatitis C or human immunodeficiency virus-positive individuals Pregnant or lactating women, or those using hormonal or unreliable contraceptive methods during the study period. Complete abstinence, intrauterine devices, double barrier methods or a vasectomized sexual partner will be considered acceptable Women with amenorrhea or suffering severe premenstrual syndrome Individuals of Asian ascent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francina Fonseca, MD, PhD
Organizational Affiliation
Parc de Salut Mar
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Clara Pérez, MD, PhD
Organizational Affiliation
Parc de Salut Mar
Official's Role
Principal Investigator
Facility Information:
Facility Name
Parc de Salut Mar (IMIM)
City
Barcelona
ZIP/Postal Code
08003
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
12637048
Citation
Blaha M, Aaslid R, Douville CM, Correra R, Newell DW. Cerebral blood flow and dynamic cerebral autoregulation during ethanol intoxication and hypercapnia. J Clin Neurosci. 2003 Mar;10(2):195-8. doi: 10.1016/s0967-5868(02)00126-1.
Results Reference
background
PubMed Identifier
16792559
Citation
Best CA, Sarkola T, Eriksson CJ, Cluette-Brown JE, Laposata M. Increased plasma fatty acid ethyl ester levels following inhibition of oxidative metabolism of ethanol by 4-methylpyrazole treatment in human subjects. Alcohol Clin Exp Res. 2006 Jul;30(7):1126-31. doi: 10.1111/j.1530-0277.2006.00138.x.
Results Reference
background
PubMed Identifier
17942435
Citation
Bottcher M, Beck O, Helander A. Evaluation of a new immunoassay for urinary ethyl glucuronide testing. Alcohol Alcohol. 2008 Jan-Feb;43(1):46-8. doi: 10.1093/alcalc/agm153. Epub 2007 Oct 17.
Results Reference
background
PubMed Identifier
3378381
Citation
Cami J, de la Torre R, Garcia-Sevilla L, Ugena B, Knobel H, Segura J. Alcohol antagonism of hypercortisolism induced by naloxone. Clin Pharmacol Ther. 1988 Jun;43(6):599-604. doi: 10.1038/clpt.1988.82.
Results Reference
background
PubMed Identifier
17159008
Citation
Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med. 2006 Dec 11-25;166(22):2437-45. doi: 10.1001/archinte.166.22.2437.
Results Reference
background
PubMed Identifier
8827968
Citation
Doyle KM, Cluette-Brown JE, Dube DM, Bernhardt TG, Morse CR, Laposata M. Fatty acid ethyl esters in the blood as markers for ethanol intake. JAMA. 1996 Oct 9;276(14):1152-6. Erratum In: JAMA 1997 Mar 12;227(10):792.
Results Reference
background
PubMed Identifier
8371143
Citation
Farre M, de la Torre R, Llorente M, Lamas X, Ugena B, Segura J, Cami J. Alcohol and cocaine interactions in humans. J Pharmacol Exp Ther. 1993 Sep;266(3):1364-73.
Results Reference
background
PubMed Identifier
17558515
Citation
Halter CC, Dresen S, Auwaerter V, Wurst FM, Weinmann W. Kinetics in serum and urinary excretion of ethyl sulfate and ethyl glucuronide after medium dose ethanol intake. Int J Legal Med. 2008 Mar;122(2):123-8. doi: 10.1007/s00414-007-0180-8. Epub 2007 Jun 9.
Results Reference
background
PubMed Identifier
17306943
Citation
Hoiseth G, Bernard JP, Karinen R, Johnsen L, Helander A, Christophersen AS, Morland J. A pharmacokinetic study of ethyl glucuronide in blood and urine: applications to forensic toxicology. Forensic Sci Int. 2007 Oct 25;172(2-3):119-24. doi: 10.1016/j.forsciint.2007.01.005. Epub 2007 Feb 16.
Results Reference
background
PubMed Identifier
18230699
Citation
Hoiseth G, Bernard JP, Stephanson N, Normann PT, Christophersen AS, Morland J, Helander A. Comparison between the urinary alcohol markers EtG, EtS, and GTOL/5-HIAA in a controlled drinking experiment. Alcohol Alcohol. 2008 Mar-Apr;43(2):187-91. doi: 10.1093/alcalc/agm175. Epub 2008 Jan 29.
Results Reference
background
PubMed Identifier
3319346
Citation
Holford NH. Clinical pharmacokinetics of ethanol. Clin Pharmacokinet. 1987 Nov;13(5):273-92. doi: 10.2165/00003088-198713050-00001.
Results Reference
background
PubMed Identifier
1991182
Citation
Johnson RD, Horowitz M, Maddox AF, Wishart JM, Shearman DJ. Cigarette smoking and rate of gastric emptying: effect on alcohol absorption. BMJ. 1991 Jan 5;302(6767):20-3. doi: 10.1136/bmj.302.6767.20.
Results Reference
background
PubMed Identifier
6370017
Citation
Jones MK, Jones BM. Ethanol metabolism in women taking oral contraceptives. Alcohol Clin Exp Res. 1984 Jan-Feb;8(1):24-8. doi: 10.1111/j.1530-0277.1984.tb05026.x.
Results Reference
background
PubMed Identifier
1131767
Citation
Kalant H, LeBlanc AE, Wilson A, Homatidis S. Sensorimotor and physiological effects of various alcoholic beverages. Can Med Assoc J. 1975 Apr 19;112(8):953-8.
Results Reference
background
PubMed Identifier
16459935
Citation
King AR, Hunter PJ. Alcohol elimination at low blood concentrations among women taking combined oral contraceptives. J Stud Alcohol. 2005 Nov;66(6):738-44. doi: 10.15288/jsa.2005.66.738.
Results Reference
background
PubMed Identifier
560303
Citation
Kopun M, Propping P. The kinetics of ethanol absorption and elimination in twins and supplementary repetitive experiments in singleton subjects. Eur J Clin Pharmacol. 1977;11(5):337-44. doi: 10.1007/BF00566530.
Results Reference
background
PubMed Identifier
16503243
Citation
Kulig CC, Beresford TP, Everson GT. Rapid, accurate, and sensitive fatty acid ethyl ester determination by gas chromatography-mass spectrometry. J Lab Clin Med. 2006 Mar;147(3):133-8. doi: 10.1016/j.lab.2005.11.006.
Results Reference
background
PubMed Identifier
7255074
Citation
Logue PE, Linnoila M, Wallman L, Erwin CW. Effects of ethanol and psychomotor tests on state anxiety: interaction with menstrual cycle in women. Percept Mot Skills. 1981 Apr;52(2):643-8. doi: 10.2466/pms.1981.52.2.643.
Results Reference
background
PubMed Identifier
6468479
Citation
Martin E, Moll W, Schmid P, Dettli L. The pharmacokinetics of alcohol in human breath, venous and arterial blood after oral ingestion. Eur J Clin Pharmacol. 1984;26(5):619-26. doi: 10.1007/BF00543496.
Results Reference
background
PubMed Identifier
20060246
Citation
Morini L, Marchei E, Vagnarelli F, Garcia Algar O, Groppi A, Mastrobattista L, Pichini S. Ethyl glucuronide and ethyl sulfate in meconium and hair-potential biomarkers of intrauterine exposure to ethanol. Forensic Sci Int. 2010 Mar 20;196(1-3):74-7. doi: 10.1016/j.forsciint.2009.12.035. Epub 2010 Jan 8.
Results Reference
background
PubMed Identifier
17250618
Citation
Morfin JP, Kulig C, Everson G, Beresford T. Controlling for serum albumin level improves the correlation between serum fatty acid ethyl esters and blood ethanol level. Alcohol Clin Exp Res. 2007 Feb;31(2):265-8. doi: 10.1111/j.1530-0277.2006.00302.x.
Results Reference
background
PubMed Identifier
10890798
Citation
Mumenthaler MS, Taylor JL, O'Hara R, Yesavage JA. Gender differences in moderate drinking effects. Alcohol Res Health. 1999;23(1):55-64.
Results Reference
background
PubMed Identifier
7053307
Citation
Nuotto E, Mattila MJ, Seppala T, Konno K. Coffee and caffeine and alcohol effects on psychomotor function. Clin Pharmacol Ther. 1982 Jan;31(1):68-76. doi: 10.1038/clpt.1982.11.
Results Reference
background
PubMed Identifier
20061103
Citation
Pragst F, Rothe M, Moench B, Hastedt M, Herre S, Simmert D. Combined use of fatty acid ethyl esters and ethyl glucuronide in hair for diagnosis of alcohol abuse: interpretation and advantages. Forensic Sci Int. 2010 Mar 20;196(1-3):101-10. doi: 10.1016/j.forsciint.2009.12.028. Epub 2010 Jan 12.
Results Reference
background
PubMed Identifier
7332732
Citation
Rangno RE, Kreeft JH, Sitar DS. Ethanol 'dose-dependent' elimination: Michaelis-Menten v classical kinetic analysis. Br J Clin Pharmacol. 1981 Nov;12(5):667-73. doi: 10.1111/j.1365-2125.1981.tb01287.x.
Results Reference
background
PubMed Identifier
11964564
Citation
Sarkola T, Iles MR, Kohlenberg-Mueller K, Eriksson CJ. Ethanol, acetaldehyde, acetate, and lactate levels after alcohol intake in white men and women: effect of 4-methylpyrazole. Alcohol Clin Exp Res. 2002 Feb;26(2):239-45.
Results Reference
background
PubMed Identifier
19759165
Citation
Schroder H, de la Torre R, Estruch R, Corella D, Martinez-Gonzalez MA, Salas-Salvado J, Ros E, Aros F, Flores G, Civit E, Farre M, Fiol M, Vila J, Fernandez-Crehuet J, Ruiz-Gutierrez V, Lapetra J, Saez G, Covas MI; PREDIMED Study Investigators. Alcohol consumption is associated with high concentrations of urinary hydroxytyrosol. Am J Clin Nutr. 2009 Nov;90(5):1329-35. doi: 10.3945/ajcn.2009.27718. Epub 2009 Sep 16.
Results Reference
background
PubMed Identifier
10585351
Citation
Soderberg BL, Sicinska ET, Blodget E, Cluette-Brown JE, Suter PM, Schuppisser T, Vetter W, Laposata M. Preanalytical variables affecting the quantification of fatty acid ethyl esters in plasma and serum samples. Clin Chem. 1999 Dec;45(12):2183-90.
Results Reference
background
PubMed Identifier
14984242
Citation
Wurst FM, Skipper GE, Weinmann W. Ethyl glucuronide--the direct ethanol metabolite on the threshold from science to routine use. Addiction. 2003 Dec;98 Suppl 2:51-61. doi: 10.1046/j.1359-6357.2003.00588.x.
Results Reference
background
PubMed Identifier
15318121
Citation
Wurst FM, Wiesbeck GA, Metzger JW, Weinmann W. On sensitivity, specificity, and the influence of various parameters on ethyl glucuronide levels in urine--results from the WHO/ISBRA study. Alcohol Clin Exp Res. 2004 Aug;28(8):1220-8. doi: 10.1097/01.alc.0000134230.21414.11.
Results Reference
background

Learn more about this trial

Non-oxidative Metabolite Profiles After Increasing Doses of Ethanol

We'll reach out to this number within 24 hrs